ARVN vs MLTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MLTX Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ARVN counters with relative strength in Valuation. Fundamentally, ARVN trades at 17.9x Forward P/E with -10.1% operating margin (-98.8% YoY revenue) versus MLTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ARVN sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ARVN | MLTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $449.9M | $1.1B | Larger Scale | MLTX |
| Trailing P/E Ratio Valuation | 17.9x | N/M | Lower Multiple | ARVN |
| Forward P/E Ratio Valuation | 17.9x | N/M | Lower Multiple | ARVN |
| Revenue Growth (YoY) Growth | -98.8% | +0.0% | Higher Growth | MLTX |
| Operating Margin (TTM) Profitability | -10.1% | 0.0% | Higher Margin | MLTX |
| Net Profit Margin Profitability | -3.5% | 0.0% | Higher Margin | MLTX |
| Return on Equity (ROE) Capital Efficiency | -1.8% | -81.5% | Higher ROE | ARVN |
| 52-Week Range Position Momentum | 5% ($6โ$15) | 17% ($9โ$23) | Stronger Trend | MLTX |
| Beta / 30D Volatility Risk Regime | 1.40ฮฒ ยท 66% Vol | 1.61ฮฒ ยท 90% Vol | Lower Realized Risk | ARVN |
| Unified Institutional Score Composite Signal | 52.9 / 100 (HOLD) | 38.3 / 100 (SELL) | Higher Composite | ARVN |